High-risk acute lymphoblastic leukemia (ALL): is there an alternative approach for increasing the number of cures?
Carella
A M
AM
Autologous Bone Marrow Transplantation Unit, Ospedale San Martino, Genova, Italy.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016913:Blood Component Transfusion; D001804:Blood Transfusion, Autologous; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D014178:Translocation, Genetic; D014916:Whole-Body Irradiation
D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin